Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.73 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.73 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317588 | 1.00 | PTGER4 (0.73) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL4993457 | 0.90 | PTGER3 (0.60) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL4990556 | 0.89 | PTGER4 (0.77) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4990561 | 0.89 | PTGER4 (0.77) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6158522 | 0.89 | PTGER4 (0.76) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6166899 | 0.89 | PTGER4 (0.76) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5812669 | 0.89 | PTGER4 (0.76) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4994629 | 0.86 | PTGER4 (0.71) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4994622 | 0.86 | PTGER4 (0.71) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6164622 | 0.86 | PTGER4 (0.76) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490055-A1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF LIVER FAILURE, LOSS OF PATENCY OF THE DUCTUS ARTERIOSUS, GLAUCOMA OR OCULAR HYPERTENSION | Pfizer Products Inc. (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | claimed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| US-6642266-B2 | Therapy of condition which presents with low bone mass in a mammal comprising administering to mammal an EP4 (prostaglandins) receptor selective agonist or prodrug | PFIZER INC. | 2003-11-04 | — | — | US | claimed |
| WO-2003077908-A1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF LIVER FAILURE, LOSS OF PATENCY OF THE DUCTUS ARTERIOSUS, GLAUCOMA OR OCULAR HYPERTENSION | PFIZER PRODUCTS INC. (US) | 2003-09-25 | — | — | WO | claimed |
| EP-1110949-B1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PROD INC (US) | 2003-09-24 | — | — | EP | claimed |
| US-20030176479-A1 | Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension | CAMERON KIMBERLY O (US) | 2003-09-18 | — | — | US | claimed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | claimed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | claimed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | claimed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005027931-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND AN EP2 OR EP4 SELECTIVE AGONIST | PFIZER PRODUCTS INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176479-A1 | Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension | PTGER4, PTGER2, PTGER1 | PTGER4 1/4885PTGER3 4/4885PTGER2 2/4885 |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20040254230-A1 | Method for treating ocular hypertension | PTGIR, PTGER4, PTGER1 | PTGER4 2/4885PTGER3 5/4885PTGER2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.